Program
Insulin Glargine
Also written as “insulin glargine”, “Insulin glargine” and “INSULIN GLARGINE”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Hyperglycemia · Glucose Intolerance, led by 9 companies.
Drug pageInsulin Glargine: every studyMany companies study it; this page follows only the 184 they lead. All 294 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofiits history only | 1241 open or running | phase 4since Sep 9, 2005 | Sep 30, 2002 | none ahead |
| Novo Nordiskits history only | 280 open or running | phase 4since Sep 12, 2005 | Oct 29, 2004 | none ahead |
| Eli Lillyits history only | 250 open or running | phase 4since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Diabetes Care Centerits history only | 20 open or running | no phasesince Apr 3, 2007 | Apr 3, 2007 | none ahead |
| Biodel | 10 open or running | phase 2since Oct 21, 2009 | Oct 21, 2009 | none ahead |
| Geropharmits history only | 10 open or running | no phasesince Sep 23, 2019 | Sep 23, 2019 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 10 open or running | phase 1since Sep 3, 2009 | Sep 3, 2009 | none ahead |
| Wockhardtits history only | 10 open or running | phase 1since May 12, 2011 | May 12, 2011 | none ahead |
Also a collaborator on its studies: PPD DEVELOPMENT, LP, Alkermes and Boehringer Ingelheim.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Biodel only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2009First study: phase 2 study in Diabetes MellitusFirst studyNCT01000922 · 24 enrolled · United States
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| insulin icodecrule | Novo Nordisk | phase 4 | 30 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
The one study Biodel leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01000922Diabetes Mellitus · United States | 2 | Completed | Jan 2008 | 24 |
How it is read
Names in the registry
- “insulin glargine”, 38 entries
- “Insulin Glargine”, 27 entries
- “Insulin glargine”, 20 entries
- “INSULIN GLARGINE”, 15 entries
- “LY2963016”, 11 entries
Codes read as this program: HOE901.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 124 studies
- Diabetes Mellitus, Type 1, 44 studies
- Diabetes Mellitus, 14 studies
- Hyperglycemia, 1 study
- Glucose Intolerance, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.